Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Debt: 2012-2024

Historic Total Debt for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $72.3 million.

  • Adma Biologics' Total Debt fell 28.52% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year decrease of 28.52%. This contributed to the annual value of $72.3 million for FY2024, which is 44.61% down from last year.
  • According to the latest figures from FY2024, Adma Biologics' Total Debt is $72.3 million, which was down 44.61% from $130.6 million recorded in FY2023.
  • Adma Biologics' Total Debt's 5-year high stood at $142.8 million during FY2022, with a 5-year trough of $72.3 million in FY2024.
  • Its 3-year average for Total Debt is $115.3 million, with a median of $130.6 million in 2023.
  • In the last 5 years, Adma Biologics' Total Debt skyrocketed by 50.56% in 2022 and then tumbled by 44.61% in 2024.
  • Adma Biologics' Total Debt (Yearly) stood at $93.0 million in 2020, then grew by 2.04% to $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then decreased by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024.